
    
      The total duration per participant was up to 52 weeks, which included 4 week screening period
      and 48 weeks study period.

      At the end of the study, the participants were invited to enter in an open-label safety study
      (LTS13588-NCT01736592) for long-term follow-up visits including ophthalmological examinations
      and recording of adverse events (AEs) for up to 15 years.
    
  